Distinguished in Camurati-Engelmann Disease

Peter D. Hughes

300 Grattan St, 
Parkville, VIC, AU 
Distinguished in Camurati-Engelmann Disease
300 Grattan St, 
Parkville, VIC, AU 
OverviewLocationsClinical Research

Overview

Peter Hughes practices in Parkville, Australia. Mr. Hughes is rated as a Distinguished expert by MediFind in the treatment of Camurati-Engelmann Disease. His top areas of expertise are Camurati-Engelmann Disease, Malignant Hypertension, D-Plus Hemolytic Uremic Syndrome, Kidney Transplant, and Tissue Biopsy.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Camurati-Engelmann Disease.

Gender
Male

Locations

300 Grattan St, Parkville, VIC 3052, Australia
Other Locations
Grattan Street, Parkville, VIC 3010, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
View 1 Less Clinical Trial

64 Total Publications

International Kidney Paired Donation Programs: Evolution and Practices of 4 Large Collaborations.
International Kidney Paired Donation Programs: Evolution and Practices of 4 Large Collaborations.
Journal: Transplantation
Published: December 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hughes's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile